We read with great interest the pilot randomized investigation by Sideris et al evaluating the vascular effects of vericiguat in heart failure with reduced ejection fraction. The study addresses an important mechanistic question: whether stimulation of soluble guanylate cyclase translates into measurable endothelial improvement beyond established guideline-directed medical therapy. This mechanistic focus is timely given the outcome benefits observed in larger trials.
The primary endpoint, brachial artery flow-mediated dilation, increased numerically by 0.7% with vericiguat compared with placebo (95% confidence interval −1.1% to 2.5%). Although exploratory, this effect size warrants clinical contextualization. Prior meta-analytic data suggest that each 1% increment in flow-mediated dilation is associated with an approximate 10% to 15% relative reduction in cardiovascular risk. A 0.7% signal, if reproducible, could therefore represent a biologically meaningful vascular shift. However, baseline flow-mediated dilation values were markedly impaired, and the supplemental data indicate modest between-group differences in shear rate area under the curve, which may influence endothelial responsiveness. Future mechanistic trials would benefit from stratification by baseline endothelial dysfunction severity and incorporation of shear-adjusted indices as coprimary measures to strengthen causal inference.
The observed reduction in log-transformed N-terminal pro–B-type natriuretic peptide of −0.42 (95% confidence interval −0.81 to −0.04) also merits deeper interpretation. While statistically nominal, the absolute between-group separation appears influenced by higher baseline concentrations in the vericiguat arm. In heart failure with reduced ejection fraction, percentage change and absolute risk translation are more clinically informative than log differences alone, particularly when baseline imbalance exists. Linking biomarker shifts to thresholds associated with hospitalization risk reduction would clarify whether the observed decrement approximates clinically actionable change. Incorporating responder analyses based on established N-terminal pro–B-type natriuretic peptide cutoffs may enhance interpretability in subsequent trials.
A further consideration relates to biological heterogeneity within the enrolled cohort. Participants were clinically stable, predominantly New York Heart Association class II, and receiving high rates of renin–angiotensin–aldosterone system inhibition and sodium–glucose cotransporter-2 inhibitors. In such optimized populations, incremental endothelial gains may be attenuated due to ceiling effects. Enrichment strategies targeting patients with residual inflammatory activation or elevated vascular stiffness could amplify the detectable vascular signal of soluble guanylate cyclase stimulation. Integrating arterial stiffness metrics or microvascular assessments alongside conduit artery flow-mediated dilation may also delineate whether vericiguat preferentially affects resistance vessel function.
Notably, the absence of parallel improvement in six-minute walk distance or Kansas City Cardiomyopathy Questionnaire overall summary score underscores the complexity of translating vascular modulation into symptomatic benefit over 12 weeks. In heart failure therapeutics, structural or neurohormonal changes frequently precede perceptible functional gains. Longer follow-up with hierarchical endpoints combining endothelial indices and clinical events would better clarify temporal sequencing.
In sum, this pilot study provides a valuable mechanistic foundation by operationalizing endothelial assessment within a randomized framework. Refinement of vascular phenotyping, biomarker contextualization, and population enrichment strategies may allow future trials to more precisely determine whether soluble guanylate cyclase stimulation confers clinically meaningful endothelial restoration in heart failure with reduced ejection fraction.
Declaration of Generative AI and AI-Assisted Technologies in the Writing Process
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
